News
-
-
-
PRESS RELEASE
BIOVERSYS SUCCESSFULLY COMPLETES ITS IPO AT CHF 36 PER SHARE AND STARTS TRADING ON THE SIX SWISS EXCHANGE TOMORROW, FEBRUARY 07, 2025
BioVersys successfully completes its IPO at CHF 36 per share, listing on SIX Swiss Exchange on February 07, 2025. The biopharmaceutical company focuses on antibacterial products against multidrug-resistant bacteria -
PRESS RELEASE
ALSO invests sustainably in infrastructure - S/4HANA Introduced in Portugal in February
ALSO invests sustainably in infrastructure with the introduction of S/4HANA in Portugal, enhancing efficiency and operational excellence. The state-of-the-art IT ecosystem includes ERP, BI, CRM, WMS, AI, security, data center, and digital platforms -
-
-
PRESS RELEASE
En vue de l’introduction en bourse de l’Helvetica Swiss Opportunity Fund le 11 février 2025, Helvetica annonce une estimation indicative de la VNI à fin 2024
L'Helvetica annonce une estimation indicative de la VNI à fin 2024 en prévision de l'introduction en bourse de l'Helvetica Swiss Opportunity Fund le 11 février 2025 -
PRESS RELEASE
Helvetica announces indicative NAV estimate for end of 2024 in view of IPO of Helvetica Swiss Opportunity Fund on 11 February 2025
Helvetica announces indicative NAV estimate for end of 2024 in view of IPO of Helvetica Swiss Opportunity Fund on 11 February 2025. Fund management discloses NAV ahead of SIX Swiss Exchange listing -
-